KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Equity Income (2020 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Equity Income for 6 consecutive years, with $14781.0 as the latest value for Q4 2025.

  • Quarterly Equity Income fell 95.07% to $14781.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, down 46.2% year-over-year, with the annual reading at $1.1 million for FY2025, 46.92% down from the prior year.
  • Equity Income hit $14781.0 in Q4 2025 for Inovio Pharmaceuticals, down from $205000.0 in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $8.5 million in Q4 2022 to a low of -$4.0 million in Q2 2022.
  • Historically, Equity Income has averaged $457245.4 across 5 years, with a median of $205000.0 in 2025.
  • Biggest five-year swings in Equity Income: plummeted 360.37% in 2021 and later soared 3715.66% in 2025.
  • Year by year, Equity Income stood at -$2.8 million in 2021, then soared by 403.96% to $8.5 million in 2022, then plummeted by 76.99% to $2.0 million in 2023, then plummeted by 84.62% to $300000.0 in 2024, then crashed by 95.07% to $14781.0 in 2025.
  • Business Quant data shows Equity Income for INO at $14781.0 in Q4 2025, $205000.0 in Q3 2025, and $759289.0 in Q2 2025.